DCLK3
Summary:
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| doublecortin like kinase 3 | MIM:613167 | Ensembl:ENSG00000163673 | HGNC:HGNC:19005 | PA162383403 | 3p22.2 |
GO terms in DCLK3
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IBA | GO:0004672 | protein kinase activity |
| MF | IEA | GO:0005524 | ATP binding |
| CC | IBA | GO:0005634 | nucleus |
| CC | IEA | GO:0005634 | nucleus |
| CC | IBA | GO:0005737 | cytoplasm |
| BP | IBA | GO:0018105 | peptidyl-serine phosphorylation |
| BP | IEA | GO:1900181 | negative regulation of protein localization to nucleus |
Gene expression in normal tissue: DCLK3
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in DCLK3
| Database | Pathway ID | Pathway Des. |
|---|
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD599 | Salermide | 3 |
| iGMDRD889 | Compound 7d-cis | 3 |
| iGMDRD248 | BRD4354 | 2 |
| iGMDRD772 | BRD4770 | 3 |
| iGMDRD151 | CHM-1 | 2 |
| iGMDRD79 | Gemcitabine | 2 |
| iGMDRD546 | BMS-754807 | 2 |
| iGMDRD427 | ABT737 | 4 |
| iGMDRD351 | GW843682X | 4 |
| iGMDRD85 | Ursolic acid | 5 |
| iGMDRD375 | GW-405833 | 2 |
| iGMDRD435 | BI-2536 | 2 |
| iGMDRD123 | Isoevodiamine | 2 |
| iGMDRD270 | Ciclosporin | 2 |
| iGMDRD121 | GMX1778 | 3 |
| iGMDRD441 | TW 37 | 3 |
| iGMDRD52 | Rotenone | 3 |
| iGMDRD870 | BRD63610 | 2 |
| iGMDRD434 | BMS-536924 | 1 |
| iGMDRD888 | Compound 44 | 3 |
| iGMDRD506 | Fedratinib | 2 |
| iGMDRD398 | Sepantronium | 4 |
| iGMDRD562 | Navitoclax | 2 |
| iGMDRD188 | Piperlongumine | 2 |
| iGMDRD23 | Gossypol | 3 |
| iGMDRD322 | FK 866 | 5 |
| iGMDRD300 | Tozasertib | 1 |
| iGMDRD246 | NPC26 | 2 |
Gene in drug-gene network: Network Plot

Gene-drug targets distribution
Gene Structure: PDB
Models in DCLK3

